home-hero-image-mobile

Vaccine Innovation. Beyond Convention.

We are dedicated to eliminating bacterial infections such as invasive pneumococcal disease, Group A Strep and Shigella to protect every child born and every adult at risk across the globe.

See Our Mission
Image for Pushing the Boundaries of What's Possible

Pushing the Boundaries of What’s Possible

Despite current efforts, Streptococcus pneumoniae bacteria continues to cause significant global morbidity and mortality, particularly for young children and older adults. This underscores the importance of advancing our potentially best-in-class pneumococcal conjugate vaccines (PCVs), including VAX-31, a 31-valent PCV, and VAX-24, a 24-valent PCV, being studied for the prevention of invasive pneumococcal disease (IPD).

Re-Engineering How Vaccines are Made

We strive to overcome the limitations of conventional, cell-based vaccine approaches using advanced chemistry and modern synthetic techniques – including our cell-free protein synthesis platform – to produce broad-spectrum vaccines that are uniquely capable of breaking down bacteria’s complex defense mechanisms while preserving robust immunogenicity.

Image for Pushing the Boundaries of What's Possible

Building a Pipeline of High-Fidelity and Broad-Spectrum Vaccines

Our PCV franchise, comprising VAX-31 and VAX-24, has the potential to improve upon existing pneumococcal vaccines, setting a new standard-of-care and raising the bar for immunogenicity. Our site-specific, carrier-sparing platform has the potential to deliver the broadest-spectrum PCVs that provide protection against both currently circulating and historically prevalent serotypes. Additional candidates in early-stage development target Group A Strep and Shigella.

Latest News

01

Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Comprehensive VAX-31 Adult Phase 3 Clinical Program, Finalized in Consultation and Alignment with FDA, Advances with Three Phase 3 Studies Underway to Support Planned BLA Submission Topline Safety, Tolerability and Immunogenicity Data from OPUS-1 Expected in Fourth Quarter of 2026; OPUS-2 and
02

Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines

Company Expects to Report Topline Data from OPUS-3 Trial and OPUS-2 Phase 3 Trial Evaluating Concomitant Administration of VAX-31 and a Seasonal Influenza Vaccine in First Half of 2027  OPUS-1, VAX-31 Adult Phase 3 Noninferiority Trial, Continues to Enroll Subjects, with Topline Data Expected in
03

Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026

SAN CARLOS, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today that it will report financial results for the fourth quarter and full year 2025 and provide a business update after market close on February 24, 2026.

Careers: Built to Scale with Purpose

Looking for higher aspirations to ignite your mind and inspire your heart? Join a team that brings grit and grace to our mission of protecting humankind from the consequences of bacterial infections.